BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Klassen SA, Senefeld JW, Johnson PW, Carter RE, Wiggins CC, Shoham S, Grossman BJ, Henderson JP, Musser J, Salazar E, Hartman WR, Bouvier NM, Liu STH, Pirofski LA, Baker SE, van Helmond N, Wright RS, Fairweather D, Bruno KA, Wang Z, Paneth NS, Casadevall A, Joyner MJ. The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis. Mayo Clin Proc 2021;96:1262-75. [PMID: 33958057 DOI: 10.1016/j.mayocp.2021.02.008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 20.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang Q, Xiang R, Huo S, Zhou Y, Jiang S, Wang Q, Yu F. Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy. Signal Transduct Target Ther 2021;6:233. [PMID: 34117216 DOI: 10.1038/s41392-021-00653-w] [Reference Citation Analysis]
2 Li Y, Zhao W, Liu J, Chen Z, Lv Q, Zhang Z. Immunotherapy Summary for Cytokine Storm in COVID-19. Front Pharmacol 2021;12:731847. [PMID: 34603047 DOI: 10.3389/fphar.2021.731847] [Reference Citation Analysis]
3 Qiao S, Zhang S, Ge J, Wang X. The spike glycoprotein of highly pathogenic human coronaviruses: structural insights for understanding infection, evolution and inhibition. FEBS Open Bio 2022. [PMID: 35689514 DOI: 10.1002/2211-5463.13454] [Reference Citation Analysis]
4 Fodor E, Müller V, Iványi Z, Berki T, Kuten Pella O, Hornyák I, Ambrus M, Sárkány Á, Skázel Á, Madár Á, Kardos D, Kemenesi G, Földes F, Nagy S, Matusovits A, János N, Tordai A, Jakab F, Lacza Z. Early Transfusion of Convalescent Plasma Improves the Clinical Outcome in Severe SARS-CoV2 Infection. Infect Dis Ther 2021. [PMID: 34817840 DOI: 10.1007/s40121-021-00514-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Niknam Z, Jafari A, Golchin A, Danesh Pouya F, Nemati M, Rezaei-Tavirani M, Rasmi Y. Potential therapeutic options for COVID-19: an update on current evidence. Eur J Med Res 2022;27:6. [PMID: 35027080 DOI: 10.1186/s40001-021-00626-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
6 Klassen SA, Senefeld JW, Senese KA, Johnson PW, Wiggins CC, Baker SE, van Helmond N, Bruno KA, Pirofski LA, Shoham S, Grossman BJ, Henderson JP, Wright RS, Fairweather D, Paneth NS, Carter RE, Casadevall A, Joyner MJ. Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence. Front Med (Lausanne) 2021;8:684151. [PMID: 34164419 DOI: 10.3389/fmed.2021.684151] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
7 Garraud O, Burnouf T. Convalescent Covid-19 plasma: Back-to-basics and ethics, and next steps. Transfus Clin Biol 2021;28:225-7. [PMID: 34362557 DOI: 10.1016/j.tracli.2021.07.005] [Reference Citation Analysis]
8 Bošnjak B, Odak I, Ritter C, Stahl K, Graalmann T, Steinbrück L, Blasczyk R, Falk CS, Schulz TF, Wedemeyer HH, Cornberg M, Ganser A, Förster R, Koenecke C. Case Report: Convalescent Plasma Therapy Induced Anti-SARS-CoV-2 T Cell Expansion, NK Cell Maturation and Virus Clearance in a B Cell Deficient Patient After CD19 CAR T Cell Therapy. Front Immunol 2021;12:721738. [PMID: 34456929 DOI: 10.3389/fimmu.2021.721738] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Hervig TA, Flesland Ø, Nissen-Meyer LSH. COVID-19 convalescent plasma: Current status, lessons from the past and future perspectives. Transfus Apher Sci 2022;:103487. [PMID: 35778352 DOI: 10.1016/j.transci.2022.103487] [Reference Citation Analysis]
10 Bernabe R, Torres C, Wangge G, Jimenez E, Karbwang J. Regulatory oversight on the use of experimental therapies during a pandemic: The case of early access to convalescent plasma therapy in three LMICs. Drug Discov Today 2021:S1359-6446(21)00536-5. [PMID: 34906688 DOI: 10.1016/j.drudis.2021.12.002] [Reference Citation Analysis]
11 Agrawal A, Jha T, Gogoi P, Diwaker P, Goel A, Khan AM, Saxena AK. Effect of Convalescent Plasma therapy on Mortality in Moderate-to-Severely Ill COVID-19 Patients. Transfusion and Apheresis Science 2022. [DOI: 10.1016/j.transci.2022.103455] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Trichel AM. Overview of Nonhuman Primate Models of SARS-CoV-2 Infection. Comp Med 2021;71:411-32. [PMID: 34548126 DOI: 10.30802/AALAS-CM-20-000119] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Peppers BP, Shmookler A, Stanley J, Giblin Sutton L, Perrotta PL, Kieffer T, Skoner D, Mahady S, Lewandrowski C, Damron H, Horspool A, Sakhjua A, McCarthy P, Hostoffer RW. Serial Convalescent Plasma Infusions for the Initial COVID-19 Infections in the Appalachian Region of West Virginia. Allergy Rhinol (Providence) 2022;13:21526575221110488. [PMID: 35795339 DOI: 10.1177/21526575221110488] [Reference Citation Analysis]
14 Hotez PJ, Batista C, Amor YB, Ergonul O, Figueroa JP, Gilbert S, Gursel M, Hassanain M, Kang G, Kaslow DC, Kim JH, Lall B, Larson H, Naniche D, Sheahan T, Shoham S, Wilder-Smith A, Sow SO, Strub-Wourgaft N, Yadav P, Bottazzi ME. Global public health security and justice for vaccines and therapeutics in the COVID-19 pandemic. EClinicalMedicine 2021;39:101053. [PMID: 34368661 DOI: 10.1016/j.eclinm.2021.101053] [Reference Citation Analysis]
15 Ceriello A, Prattichizzo F. Pharmacological management of COVID-19 in type 2 diabetes. J Diabetes Complications 2021;35:107927. [PMID: 33896714 DOI: 10.1016/j.jdiacomp.2021.107927] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
16 Lattanzio N, Acosta-Diaz C, Villasmil RJ, Kirkland Z, Bass C, Yenari S, Conte J, Dawkins K, Fonseca T, Grimes C, Stewart A, Geary ME, Vore H, Hamad K, Wiese-Rometsch W, Fiorica J, Gordillo M, Mercado R, Voelker K. Effectiveness of COVID-19 Convalescent Plasma Infusion Within 48 Hours of Hospitalization With SARS-CoV-2 Infection. Cureus 2021;13:e16746. [PMID: 34513370 DOI: 10.7759/cureus.16746] [Reference Citation Analysis]
17 Al-Hajri QR, Alfayez A, Alsalman D, Alanezi F, Alhodaib H, Al-Rayes SA, Aljaffary A, AlThani B, AlNujaidi H, Al-Saif AK, Attar R, Aljabri D, Al-Mubarak S, Al-Juwair MM, Alrawiai S, Alanzi TM. The Impact of WhatsApp on the Blood Donation Process in Saudi Arabia. J Blood Med 2021;12:1003-10. [PMID: 34824556 DOI: 10.2147/JBM.S339521] [Reference Citation Analysis]
18 González SE, Regairaz L, Salazar MR, Ferrando NS, González Martínez VV, Carrera Ramos PM, Pesci SA, Vidal JM, Kreplak N, Estenssoro E. Timing of convalescent plasma administration and 28-day mortality in COVID-19 pneumonia. J Investig Med. [DOI: 10.1136/jim-2021-002158] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Larkey NE, Ewaisha R, Lasho MA, Roforth MM, Granger D, Jerde CR, Wu L, Gorsh A, Klassen SA, Senefeld JW, Joyner MJ, Baumann NA, Theel ES, Mills JR, Szymczak WA. Limited Correlation between SARS-CoV-2 Serologic Assays for Identification of High-Titer COVID-19 Convalescent Plasma Using FDA Thresholds. Microbiol Spectr. [DOI: 10.1128/spectrum.01154-22] [Reference Citation Analysis]
20 Senefeld JW, Johnson PW, Kunze KL, Bloch EM, van Helmond N, Golafshar MA, Klassen SA, Klompas AM, Sexton MA, Diaz Soto JC, Grossman BJ, Tobian AAR, Goel R, Wiggins CC, Bruno KA, van Buskirk CM, Stubbs JR, Winters JL, Casadevall A, Paneth NS, Shaz BH, Petersen MM, Sachais BS, Buras MR, Wieczorek MA, Russoniello B, Dumont LJ, Baker SE, Vassallo RR, Shepherd JRA, Young PP, Verdun NC, Marks P, Haley NR, Rea RF, Katz L, Herasevich V, Waxman DA, Whelan ER, Bergman A, Clayburn AJ, Grabowski MK, Larson KF, Ripoll JG, Andersen KJ, Vogt MNP, Dennis JJ, Regimbal RJ, Bauer PR, Blair JE, Buchholtz ZA, Pletsch MC, Wright K, Greenshields JT, Joyner MJ, Wright RS, Carter RE, Fairweather D. Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study. PLoS Med 2021;18:e1003872. [PMID: 34928960 DOI: 10.1371/journal.pmed.1003872] [Reference Citation Analysis]
21 Senefeld JW, Klassen SA, Ford SK, Senese KA, Wiggins CC, Bostrom BC, Thompson MA, Baker SE, Nicholson WT, Johnson PW, Carter RE, Henderson JP, Hartman WR, Pirofski LA, Wright RS, Fairweather L, Bruno KA, Paneth NS, Casadevall A, Joyner MJ. Use of convalescent plasma in COVID-19 patients with immunosuppression. Transfusion 2021;61:2503-11. [PMID: 34036587 DOI: 10.1111/trf.16525] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
22 Gupta SL, Jaiswal RK. Neutralizing antibody: a savior in the Covid-19 disease. Mol Biol Rep 2022;49:2465-74. [PMID: 34988889 DOI: 10.1007/s11033-021-07020-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
23 Paneth N, Joyner MJ, Casadevall A. Finding evidence for treatment decisions in a pandemic. Trends in Molecular Medicine 2022. [DOI: 10.1016/j.molmed.2022.04.008] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Ling RR, Sim JJL, Tan FL, Tai BC, Syn N, Mucheli SS, Fan BE, Mitra S, Ramanathan K. Convalescent Plasma for Patients Hospitalized With Coronavirus Disease 2019: A Meta-Analysis With Trial Sequential Analysis of Randomized Controlled Trials. Transfus Med Rev 2021:S0887-7963(21)00056-0. [PMID: 34782209 DOI: 10.1016/j.tmrv.2021.09.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
25 Leon J, Merrill AE, Rogers K, Kurt J, Dempewolf S, Ehlers A, Jackson JB, Knudson CM. SARS-CoV-2 antibody changes in patients receiving COVID-19 convalescent plasma from normal and vaccinated donors. Transfus Apher Sci 2021;:103326. [PMID: 34862140 DOI: 10.1016/j.transci.2021.103326] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Körper S, Weiss M, Zickler D, Wiesmann T, Zacharowski K, Corman VM, Grüner B, Ernst L, Spieth P, Lepper PM, Bentz M, Zinn S, Paul G, Kalbhenn J, Dollinger MM, Rosenberger P, Kirschning T, Thiele T, Appl T, Mayer B, Schmidt M, Drosten C, Wulf H, Kruse JM, Jungwirth B, Seifried E, Schrezenmeier H; CAPSID Clinical Trial Group. Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19. J Clin Invest 2021;131:e152264. [PMID: 34464358 DOI: 10.1172/JCI152264] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
27 Ma T, Wiggins CC, Kornatowski BM, Hailat RS, Clayburn AJ, Guo WL, Johnson PW, Senefeld JW, Klassen SA, Baker SE, Bruno KA, Fairweather D, Wright RS, Carter RE, Li C, Joyner MJ, Paneth NS. The Role of Disease Severity and Demographics in the Clinical Course of COVID-19 Patients Treated With Convalescent Plasma. Front Med (Lausanne) 2021;8:707895. [PMID: 35155458 DOI: 10.3389/fmed.2021.707895] [Reference Citation Analysis]
28 Cao H, Ming L, Chen L, Zhu X, Shi Y. The Effectiveness of Convalescent Plasma for the Treatment of Novel Corona Virus Disease 2019: A Systematic Review and Meta-Analysis. Front Med (Lausanne) 2021;8:641429. [PMID: 34646833 DOI: 10.3389/fmed.2021.641429] [Reference Citation Analysis]
29 Beraud M, Goodhue Meyer E, Lozano M, Bah A, Vassallo R, Brown BL. Lessons learned from the use of convalescent plasma for the treatment of COVID-19 and specific considerations for immunocompromised patients. Transfusion and Apheresis Science 2022. [DOI: 10.1016/j.transci.2022.103355] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Franchini M, Cruciani M. How Safe Is COVID-19 Convalescent Plasma? Mayo Clin Proc 2021;96:2279-81. [PMID: 34353475 DOI: 10.1016/j.mayocp.2021.06.011] [Reference Citation Analysis]
31 Focosi D, Franchini M, Pirofski LA, Burnouf T, Paneth N, Joyner MJ, Casadevall A. COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes. Clin Microbiol Rev 2022;:e0020021. [PMID: 35262370 DOI: 10.1128/cmr.00200-21] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
32 Lanza F, Agostini V, Monaco F, Passamonti F, Seghatchian J. Therapeutic Use of Convalescent Plasma in COVID-19 Infected Patients with Concomitant Hematological Disorders. Clin Hematol Int 2021;3:77-82. [PMID: 34820612 DOI: 10.2991/chi.k.210403.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Razumikhin M, Smolyanova T, Nikolaeva A, Orlova E, Ivanov A, Belyakova O, Vyaznikova T, Selezneva N, Perevozchikov A, Sokolova A, Zubkova N, Efimova I, Dolzhikova I, Logunov D, Sakanjan E. Development and characterization of anti-SARS-CoV-2 intravenous immunoglobulin from COVID-19 convalescent plasma. Immunotherapy 2022. [PMID: 35892311 DOI: 10.2217/imt-2022-0015] [Reference Citation Analysis]
34 Husniah H, Ruhanda R, Supriatna AK, Biswas MHA. SEIR Mathematical Model of Convalescent Plasma Transfusion to Reduce COVID-19 Disease Transmission. Mathematics 2021;9:2857. [DOI: 10.3390/math9222857] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
35 Chowdhry M, Hussain M, Singh P, Lekshmi M, Agrawal S, Kanwar M, Chawla R, Kantroo V, Bali R, Bansal A, Chawla A, Modi N, Mishra M, Khan Z. CONVALESCENT PLASMA- AN INSIGHT INTO A NOVEL TREATMENT OF COVID-19 ICU PATIENTS. Transfusion and Apheresis Science 2022. [DOI: 10.1016/j.transci.2022.103497] [Reference Citation Analysis]
36 Lyman GH, Desai A, Leyfman Y, Kuderer NM. Opportunities and Challenges of Observational Studies and Randomized Controlled Trials for Evaluating the Therapeutic Efficacy of COVID-19 Convalescent Plasma. Cancer Invest 2021;39:449-56. [PMID: 34134587 DOI: 10.1080/07357907.2021.1942127] [Reference Citation Analysis]
37 Fanning SL, Korngold R, Yang Z, Goldgirsh K, Park S, Zenreich J, Baker M, McKiernan P, Tan M, Zhang B, Donato ML, Perlin DS. Elevated cytokines and chemokines in peripheral blood of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma. PLoS Pathog 2021;17:e1010025. [PMID: 34714894 DOI: 10.1371/journal.ppat.1010025] [Reference Citation Analysis]
38 Fernández-lázaro D, Ortega CD, Sánchez-serrano N, Beddar Chaib F, Jerves Donoso D, Jiménez-callejo E, Rodríguez-garcía S. Convalescent Plasma Therapy, Therapeutic Formulations of Repurposed Drugs in 20th Century Epidemics against COVID-19: A Systematic Review. Pharmaceutics 2022;14:1020. [DOI: 10.3390/pharmaceutics14051020] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Schmidt AE, Vogel P, Chastain CA, Barnes T, Roth NJ, Simon TL. Analysis of 52 240 source plasma donors of convalescent COVID-19 plasma: Sex, ethnicity, and age association with initial antibody levels and rate of dissipation. J Clin Apher 2022. [PMID: 35815776 DOI: 10.1002/jca.21998] [Reference Citation Analysis]
40 Troxel AB, Petkova E, Goldfeld K, Liu M, Tarpey T, Wu Y, Wu D, Agarwal A, Avendaño-solá C, Bainbridge E, Bar KJ, Devos T, Duarte RF, Gharbharan A, Hsue PY, Kumar G, Luetkemeyer AF, Meyfroidt G, Nicola AM, Mukherjee A, Ortigoza MB, Pirofski L, Rijnders BJA, Rokx C, Sancho-lopez A, Shaw P, Tebas P, Yoon H, Grudzen C, Hochman J, Antman EM. Association of Convalescent Plasma Treatment With Clinical Status in Patients Hospitalized With COVID-19: A Meta-analysis. JAMA Netw Open 2022;5:e2147331. [DOI: 10.1001/jamanetworkopen.2021.47331] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
41 Clark NM, Janaka SK, Hartman W, Stramer S, Goodhue E, Weiss J, Evans DT, Connor JP. Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not facilitate antibody-dependent enhance of viral infection. bioRxiv 2021:2021. [PMID: 34545365 DOI: 10.1101/2021.09.14.460394] [Reference Citation Analysis]
42 Volk A, Covini-Souris C, Kuehnel D, De Mey C, Römisch J, Schmidt T. SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin. BioDrugs 2021. [PMID: 34843105 DOI: 10.1007/s40259-021-00511-9] [Reference Citation Analysis]
43 Wouters E, Verbrugghe C, Devloo R, Debruyne I, De Clippel D, Van Heddegem L, Van Asch K, Van Gaver V, Vanbrabant M, Muylaert A, Compernolle V, Feys HB. A novel competition ELISA for the rapid quantification of SARS-CoV-2 neutralizing antibodies in convalescent plasma. Transfusion 2021;61:2981-90. [PMID: 34498761 DOI: 10.1111/trf.16652] [Reference Citation Analysis]
44 Klompas AM, van Helmond N, Juskewitch JE, Pruthi RK, Sexton MA, Soto JCD, Klassen SA, Senese KA, van Buskirk CM, Winters JL, Stubbs JR, Hammel SA, Joyner MJ, Senefeld JW. Coagulation profile of human COVID-19 convalescent plasma. Sci Rep 2022;12:637. [PMID: 35022488 DOI: 10.1038/s41598-021-04670-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Clark NM, Janaka SK, Hartman W, Stramer S, Goodhue E, Weiss J, Evans DT, Connor JP. Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not enhance viral infection. PLoS One 2022;17:e0257930. [PMID: 35259162 DOI: 10.1371/journal.pone.0257930] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Sachdev S, Pathak S, Sharma RR, Mahapatra M. Convalescent Plasma the Old Warhorse First to be Inducted in Pandemics is not the Zippy Chippy of Derby. Indian J Hematol Blood Transfus 2021;:1-2. [PMID: 34177140 DOI: 10.1007/s12288-021-01457-2] [Reference Citation Analysis]
47 Cusi MG, Conticini E, Gandolfo C, Anichini G, Savellini GG, Valente S, Franchi F, Scolletta S, Percivalle E, Frediani B. Hyperimmune plasma in three immuno-deficient patients affected by non-severe, prolonged COVID-19: a single-center experience. BMC Infect Dis 2021;21:630. [PMID: 34210259 DOI: 10.1186/s12879-021-06321-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Ordaya EE, Abu Saleh OM, Stubbs JR, Joyner MJ. Vax-Plasma in Patients With Refractory COVID-19. Mayo Clin Proc 2022;97:186-9. [PMID: 34996552 DOI: 10.1016/j.mayocp.2021.11.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
49 Franchini M, Corsini F, Focosi D, Cruciani M. Safety and Efficacy of Convalescent Plasma in COVID-19: An Overview of Systematic Reviews. Diagnostics (Basel) 2021;11:1663. [PMID: 34574004 DOI: 10.3390/diagnostics11091663] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Cho K, Keithly SC, Kurgansky KE, Madenci AL, Gerlovin H, Wellman HM, Doubleday A, Thomas ER, Park Y, Ho YA, Sugimoto JD, Moore KP, Peterson AC, Hoag C, Gupta K, Jeans K, Klote M, Ramoni R, Huang GD, Casas JP, Gagnon DR, Hernán MA, Smith NL, Gaziano JM. Early Convalescent Plasma Therapy and Mortality among US Veterans Hospitalized with Non-Severe COVID-19: An Observational Analysis Emulating a Target Trial. J Infect Dis 2021:jiab330. [PMID: 34153099 DOI: 10.1093/infdis/jiab330] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Paneth NS, Joyner MJ, Casadevall A. The fossilization of randomized clinical trials. J Clin Invest 2022;132:e158499. [PMID: 35166241 DOI: 10.1172/JCI158499] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
52 Thomopoulos TP, Rosati M, Terpos E, Stellas D, Hu X, Karaliota S, Bouchla A, Katagas I, Antoniadou A, Mentis A, Papageorgiou SG, Politou M, Bear J, Donohue D, Kotanidou A, Kalomenidis I, Korompoki E, Burns R, Pagoni M, Grouzi E, Labropoulou S, Stamoulis K, Bamias A, Tsiodras S, Dimopoulos MA, Pavlakis GN, Pappa V, Felber BK. Kinetics of Nucleocapsid, Spike and Neutralizing Antibodies, and Viral Load in Patients with Severe COVID-19 Treated with Convalescent Plasma. Viruses 2021;13:1844. [PMID: 34578426 DOI: 10.3390/v13091844] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Qi H, Liu B, Wang X, Zhang L. The humoral response and antibodies against SARS-CoV-2 infection. Nat Immunol 2022;23:1008-20. [PMID: 35761083 DOI: 10.1038/s41590-022-01248-5] [Reference Citation Analysis]
54 De Silvestro G, Marson P, La Raja M, Cattelan AM, Guarnieri G, Monticelli J, Tiberio I, Vianello A, Gandini G, Gessoni G, Fiorin F, Sardella C, Astolfi L, Saia M; Veneto Hospitals. Outcome of SARS CoV-2 inpatients treated with convalescent plasma: One-year of data from the Veneto region (Italy) Registry. Eur J Intern Med 2021:S0953-6205(21)00433-7. [PMID: 34980505 DOI: 10.1016/j.ejim.2021.12.023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
55 Joyner MJ, Klompas AM, Klassen SA, Senefeld JW, Fairweather D, Wright RS, Carter RE. In Reply-How Safe Is COVID-19 Convalescent Plasma? Mayo Clin Proc 2021;96:2281-2. [PMID: 34353476 DOI: 10.1016/j.mayocp.2021.06.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Nixon DF, Marín-Hernández D, Hupert N. Extreme immunotherapy: emergency immunology to defeat pandemics. Mol Med 2021;27:112. [PMID: 34530723 DOI: 10.1186/s10020-021-00366-4] [Reference Citation Analysis]
57 Vercueil C, Eberst L, Humbrecht C, Fornecker LM. Efficacy of Serotherapy on an N501Y Variant of SARS-CoV-2 in a Patient With Chronic Lymphocytic Leukemia. Hemasphere 2021;5:e655. [PMID: 34881357 DOI: 10.1097/HS9.0000000000000655] [Reference Citation Analysis]
58 Farhangnia P, Dehrouyeh S, Safdarian AR, Farahani SV, Gorgani M, Rezaei N, Akbarpour M, Delbandi A. Recent Advances in Passive Immunotherapies for COVID-19: The Evidence-Based Approaches and Clinical Trials. International Immunopharmacology 2022. [DOI: 10.1016/j.intimp.2022.108786] [Reference Citation Analysis]